Gilead posts solid Q1 2026 growth & raises full-year outlook on HIV momentum

CORONA Remedies posts robust FY26 with 17.3% revenue growth, 33.4% PAT surge

The company highlighted a series of strategic moves during the year, including the acquisition of WOKADINE, marking its entry into the Rs. 648 Cr Povidone Iodine market

FDA okays RIVANNA’s AI-powered Accuro XV ultrasound system

The clearance marks a pivotal step forward for the company as it pushes deeper into AI-driven diagnostics and expands its clinical footprint in point-of-care imaging

JB Chemicals reports muted Q4 FY26 as integration resets business

The CDMO segment saw a 22% decline in Q4 due to a strong base in the prior year

Shareholders approve J.B. Pharma merger with Torrent Pharma

Proposed amalgamation now awaits NCLT approval; shareholders to receive 51 Torrent Pharma shares for every 100 JB Pharma shares held

Symeres appoints Henning Steinhagen as CEO to drive next phase of global growth

Steinhagen brings more than 25 years of leadership experience spanning pharma, biotech and the CRO/CDMO sector

Lonza surges on biologics boom

Expands manufacturing push & locks in major growth deals

Roche moves to acquire PathAI for up to $1.05 billion in major AI pathology push

The acquisition positions Roche more aggressively in digital pathology and precision diagnostics capabilities

Bayer strikes $2.45 billion deal for breakthrough blindness drug developer Perfuse Therapeutics

The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy

Safic-Alcan expands in India with majority stake in SA Ingredients

The deal brings SAI — a key distributor serving pharmaceutical and nutraceutical manufacturers — into the Safic-Alcan Group’s expanding Asia footprint